Walter V. Klemp - Jul 2, 2023 Form 4 Insider Report for Moleculin Biotech, Inc. (MBRX)

Role: CEO and President, Director
Signature: /s/ Jonathan P. Foster by Power of Attorney
Stock symbol: MBRX
Transactions as of: Jul 2, 2023
Transactions value $: -$2,074
Form type: 4
Date filed: 7/5/2023, 06:00 PM
Previous filing: Jun 26, 2023
Next filing: Jul 13, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MBRX	Common Stock	Options Exercise		+14.7K	+3.12%		486K	Jul 2, 2023	Direct	F1
transaction	MBRX	Common Stock	Tax liability	-$2.07K	-3.58K	-0.74%	$0.58	482K	Jul 2, 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MBRX	Restricted Stock Units	Options Exercise	$0	-14.7K	-0.75%	$0.00	1.94M	Jul 2, 2023	Common Stock	14.7K		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Restricted stock units convert into common stock on a one-for-one basis.
F2	Shares withheld for payment of taxes upon vesting of restricted stock unit awards.
F3	On July 2, 2020, the reporting person was granted 58,869 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.